SUSTAIN 8:每周一次司马鲁肽对比每日卡格列净作为二甲双胍附加治疗的疗效与安全性
SUSTAIN 8 是一项双盲 3b 期随机对照试验,纳入 788 例二甲双胍控制不佳的 2 型糖尿病患者,比较每周一次司马鲁肽 1.0 mg 与每日卡格列净 300 mg。52 周时司马鲁肽在降低 HbA1c 和体重方面均优于卡格列净,胃肠道不良事件更常见,而卡格列净感染事件更多。
要点
- 司马鲁肽组恶心等胃肠道不良事件发生率为 47%,卡格列净组感染为 35%。
- 司马鲁肽因不良事件停药率 10%,高于卡格列净的 5%。
核心结论
- 在二甲双胍控制不佳的 2 型糖尿病患者中,每周一次司马鲁肽 1.0 mg 在降低 HbA1c 和体重方面优于每日卡格列净 300 mg。
研究设计与样本
- 多中心、双盲、平行组、3b 期随机对照试验,在 11 个国家 111 个中心进行。
- 788 例患者按 1:1 随机分配至皮下司马鲁肽 1.0 mg 每周一次(394 例)或口服卡格列净 300 mg 每日一次(394 例)。
- 主要终点为第 52 周 HbA1c 自基线变化,确证性次要终点为体重自基线变化。
主要发现
- 司马鲁肽组胃肠道不良事件最常见为恶心,发生于 392 例中的 184 例(47%)。
- 卡格列净组感染和侵染(最常见为尿路感染)更常见,发生于 394 例中的 136 例(35%)。
- 因不良事件提前停药:司马鲁肽组 392 例中 38 例(10%),卡格列净组 394 例中 20 例(5%)。
临床怎么用
- 对于二甲双胍控制不佳的 2 型糖尿病患者,选择司马鲁肽 1.0 mg 每周一次较卡格列净 300 mg 每日一次可带来更优的血糖和体重获益。
- 临床决策需权衡胃肠道不良反应(司马鲁肽)与感染风险(卡格列净)及停药率差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the efficacy and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozin (an SGLT2 inhibitor) in patients with type 2 diabetes. METHODS: This was a double-blind, parallel-group, phase 3b, randomised controlled trial done at 111 centres in 11 countries. Eligible patients were at least 18 years old and had uncontrolled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) on stable daily metformin therapy. Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1·0 mg once weekly or oral canagliflozin 300 mg once daily. The primary endpoint was change from baseline in HbA1c, and the confirmatory secondary endpoint was change from baseline in bodyweight, both at week 52. The primary analysis population included all randomly assigned patients, using on-treatment data collected before initiation of rescue medication. The safety analysis was done on a population that included all patients exposed to at least one dose of trial product. The trial was powered for HbA1c and bodyweight superiority under reasonable assumptions. This trial is registered with ClinicalTrials.gov, NCT03136484. FINDINGS: Between March 15, 2017, and Nov 16, 2018, 788 patients were randomly assigned to semaglutide 1·0 mg (394 patients) or canagliflozin 300 mg (394 patients). 739 patients completed the trial (367 in the semaglutide group and 372 in the canagliflozin group). From overall baseline mean, patients receiving semaglutide had significantly greater reductions in HbA1c and bodyweight than those receiving canagliflozin (HbA1c estimated treatment difference [ETD] -0·49 percentage points, 95% CI -0·65 to -0·33; -5·34 mmol/mol, 95% CI -7·10 to -3·57; p<0·0001; and bodyweight ETD -1·06 kg, 95% CI -1·76 to -0·36; p=0·0029). Gastrointestinal disorders, most commonly nausea, were the most frequently reported adverse events with semaglutide, occurring in 184 (47%) of 392 patients; whereas infections and infestations (defined using the Medical Dictionary for Regulatory Activities, version 21.0), most commonly urinary tract infections, occurred more frequently with canagliflozin, in 136 (35%) of 394 patients. Premature treatment discontinuation because of adverse events occurred in 38 (10%) of 392 patients with semaglutide and in 20 (5%) of 394 patients with canagliflozin. One fatal adverse event confirmed unlikely to be caused by treatment occurred in the semaglutide group. INTERPRETATION: Once-weekly semaglutide 1·0 mg was superior to daily canagliflozin 300 mg in reducing HbA1c and bodyweight in patients with type 2 diabetes uncontrolled on metformin therapy. These outcomes might guide treatment intensification choices. FUNDING: Novo Nordisk.
引用
- Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019. PMID: 31540867. doi:10.1016/S2213-8587(19)30311-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。